| Filed On | Filing |
|---|---|
| 09 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook |
| 04 Sep 2026 |
Form 4: Moatazedi David, Director
Sold 105,108 shares ($950K) |
| 02 Sep 2026 | 144 |
| 31 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook |
| 04 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets |
| 08 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality |
| 12 Jun 2026 | EFFECT |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on three proposals, as further described in the Company’s definitive proxy stateme... |
| 10 Jun 2026 | CORRESP |
| 10 Jun 2026 | UPLOAD |
| 05 Jun 2026 | S-3 |
| 04 May 2026 | 10-Q |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook |
| 29 Apr 2026 | DEFA14A |
| 29 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $6.4M, down 8.4% · say-on-pay vote |
| 29 Apr 2026 | ARS |
Loading...